### SUPPLEMENTAL FILE 2. Patient characteristics of TAD-patients and screening-participants

<table>
<thead>
<tr>
<th>Total (n=261)</th>
<th>TAD patients (n=147)</th>
<th>Screening-participants (n=114)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age - y</strong></td>
<td>52.9±15.8</td>
<td>59.2±12.6</td>
<td>44.9±15.9</td>
</tr>
<tr>
<td><strong>Sex - % female</strong></td>
<td>125 (47.9)</td>
<td>54 (36.7)</td>
<td>71 (62.3)</td>
</tr>
<tr>
<td><strong>Length - cm</strong></td>
<td>177.2±14.7</td>
<td>178.4±14.2</td>
<td>175.6±15.3</td>
</tr>
<tr>
<td><strong>Weight - kg</strong></td>
<td>83.9±19.4</td>
<td>87.9±19.1</td>
<td>78.7±18.6</td>
</tr>
<tr>
<td><strong>BSA - m²</strong></td>
<td>2.0±0.2</td>
<td>2.0±0.2</td>
<td>1.9±0.2</td>
</tr>
<tr>
<td><strong>Hypertension</strong></td>
<td>117 (44.8)</td>
<td>84 (57.1)</td>
<td>33 (28.9)</td>
</tr>
<tr>
<td><strong>Hyperlipidemia</strong></td>
<td>66 (25.3)</td>
<td>51 (34.7)</td>
<td>(28.9)</td>
</tr>
<tr>
<td><strong>Smoking</strong></td>
<td>25 (9.6)</td>
<td>13 (8.8)</td>
<td>12 (10.5)</td>
</tr>
<tr>
<td><strong>Diabetes</strong></td>
<td>9 (3.4)</td>
<td>7 (4.8)</td>
<td>2 (1.8)</td>
</tr>
<tr>
<td><strong>Renal dysfunction</strong></td>
<td>5 (1.9)</td>
<td>4 (2.7)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td><strong>History of depression</strong></td>
<td>16 (6.1)</td>
<td>8 (5.4)</td>
<td>8 (7.0)</td>
</tr>
<tr>
<td><strong>History of anxiety disorder</strong></td>
<td>4 (1.5)</td>
<td>2 (1.4)</td>
<td>2 (1.8)</td>
</tr>
<tr>
<td><strong>Beta blocker use</strong></td>
<td>60 (23.0)</td>
<td>50 (34.0)</td>
<td>10 (8.8)</td>
</tr>
<tr>
<td><strong>ARB use</strong></td>
<td>34 (13.0)</td>
<td>30 (20.4)</td>
<td>4 (3.5)</td>
</tr>
<tr>
<td><strong>ACEi use</strong></td>
<td>42 (16.1)</td>
<td>32 (21.8)</td>
<td>10 (8.8)</td>
</tr>
<tr>
<td><strong>Diagnosis</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marfan Syndrome</td>
<td>10 (3.8)</td>
<td>6 (4.1)</td>
<td>4 (3.5)</td>
</tr>
<tr>
<td>Loeys-Dietz Syndrome</td>
<td>10 (3.8)</td>
<td>4 (2.7)</td>
<td>6 (5.3)</td>
</tr>
<tr>
<td>Ehlers-Danlos Syndrome</td>
<td>2 (0.8)</td>
<td>0 (0.0)</td>
<td>2 (1.8)</td>
</tr>
<tr>
<td>Other</td>
<td>12 (4.6)</td>
<td>2 (1.4)</td>
<td>10 (8.8)</td>
</tr>
<tr>
<td>Confirmed genetic mutation</td>
<td>61 (23.4)</td>
<td>31 (21.1)</td>
<td>30 (26.3)</td>
</tr>
<tr>
<td>Positive family history aortic disease</td>
<td>132 (50.6)</td>
<td>60 (40.8)</td>
<td>72 (63.2)</td>
</tr>
<tr>
<td>Abdominal aortic aneurysm</td>
<td>9 (3.4)</td>
<td>8 (5.9)</td>
<td>1 (0.8)</td>
</tr>
<tr>
<td>Maximal diameter aortic root¹</td>
<td>37.6±5.7</td>
<td>40.4±5.5</td>
<td>34.3±4.0</td>
</tr>
<tr>
<td>Indexed diameter aortic root¹ - mm/BSA</td>
<td>19.0±2.9</td>
<td>19.7±3.0</td>
<td>18.0±2.5</td>
</tr>
<tr>
<td>Maximal diameter ascending aorta¹</td>
<td>37.0±6.8</td>
<td>40.8±5.5</td>
<td>32.2±5.1</td>
</tr>
<tr>
<td>Indexed diameter ascending aorta¹ - mm/BSA</td>
<td>18.7±3.9</td>
<td>20.1±3.7</td>
<td>16.8±3.2</td>
</tr>
<tr>
<td>Maximal diameter descending aorta¹</td>
<td>27.1±6.3</td>
<td>30.0±5.9</td>
<td>23.9±5.2</td>
</tr>
<tr>
<td>Indexed diameter descending aorta¹ - mm/BSA</td>
<td>13.7±3.3</td>
<td>14.7±3.3</td>
<td>12.5±2.9</td>
</tr>
<tr>
<td>Previous aortic surgery</td>
<td>33 (12.6)</td>
<td>32 (21.8)</td>
<td>1 (0.9)</td>
</tr>
<tr>
<td>Previous dissection</td>
<td>23 (8.8)</td>
<td>20 (13.6)</td>
<td>3 (2.6)</td>
</tr>
<tr>
<td>Current partner</td>
<td>126 (75.9)</td>
<td>50 (66.7)</td>
<td>76 (83.5)</td>
</tr>
<tr>
<td>Current employment²</td>
<td>103 (39.5)</td>
<td>61 (51.7)</td>
<td>42 (48.8)</td>
</tr>
<tr>
<td>Paid job</td>
<td>96 (36.8)</td>
<td>57 (48.3)</td>
<td>39 (45.3)</td>
</tr>
<tr>
<td>Volunteer work</td>
<td>7 (2.7)</td>
<td>4 (3.4)</td>
<td>3 (3.5)</td>
</tr>
<tr>
<td>Retired</td>
<td>57 (21.8)</td>
<td>43 (36.4)</td>
<td>14 (16.3)</td>
</tr>
<tr>
<td>Student</td>
<td>16 (6.1)</td>
<td>1 (0.8)</td>
<td>15 (17.4)</td>
</tr>
<tr>
<td>Unable to work / disabled</td>
<td>16 (6.1)</td>
<td>10 (8.5)</td>
<td>6 (7.0)</td>
</tr>
<tr>
<td>Unemployed</td>
<td>12 (4.6)</td>
<td>3 (2.5)</td>
<td>9 (10.5)</td>
</tr>
<tr>
<td>Exercise</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sports participation²</td>
<td>105 (40.2)</td>
<td>50 (34.0)</td>
<td>55 (48.2)</td>
</tr>
<tr>
<td>Walking or cycling</td>
<td>104 (39.8)</td>
<td>63 (42.9)</td>
<td>41 (36.0)</td>
</tr>
<tr>
<td>None</td>
<td>36 (13.8)</td>
<td>24 (16.3)</td>
<td>12 (10.5)</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD or as absolute and percentage. BSA=Body Surface Area; ARB= Angiotensin II receptor blocker; ACEi= Angiotensin Converting Enzyme inhibitor; LVEF= left ventricular ejection fraction; MFS= Marfan Syndrome; LDS 3= Loeys-Diastlastic Syndrome.
Dietz Syndrome type 3 (SMAD3 mutation).

1. Only patients without previous aortic surgery.
2. Current employment = Paid job or volunteer work.
3. Defined as: Participating in any sport other than daily walking or cycling at any level at least once a week.

* Significant at the 0.05 level
** Significant at the 0.01 level